Edvince AB granted EU Orphan Medicinal Product Designation for EDV2209 in treatment of non-traumatic subarachnoid hemorrhage
On November 8th Edvince AB received a positive decision from the European Commission, granting the EDV2209 drug Orphan Medicinal Product Designation for treatment of non-traumatic subarachnoid hemorrhage. Edvince AB is a Life Science R&D company that develops a new treatment to minimize brain damage in patients that has suffered a bleeding in the brain – […]
Edvince AB was granted FDA Orphan-Drug Designation for EDV2209 in treatment of subarachnoid hemorrhage
Edvince AB, a biotech company that is developing a new treatment concept to minimize brain damage subsequent to cerebral ischemia, received a positive response from the US Food and Drug Administration (FDA) on august 3rd, granting the EDV2209 drug orphan-drug designation for treatment of subarachnoid hemorrhage.
Bioteknikbolaget Edvince AB, som utvecklar en ny behandling för att minimera skador på hjärnan vid stroke, utökar styrelsen med nuvarande Vd Sarah Fredriksson och inleder rekrytering av ny Vd. Source: Pressmeddelanden